United States - English - NLM (National Library of Medicine)

biocomp pharma, inc. - ascorbic acid (unii: pq6ck8pd0r) (ascorbic acid - unii:pq6ck8pd0r), iron pentacarbonyl (unii: 6wq62taq6z) (ferrous cation - unii:gw89581owr), docusate sodium (unii: f05q2t2ja0) (docusate - unii:m7p27195ag), ferrous gluconate (unii: u1b11i423z) (ferrous cation - unii:gw89581owr), folic acid (unii: 935e97boy8) (folic acid - unii:935e97boy8), cyanocobalamin (unii: p6yc3eg204) (cyanocobalamin - unii:p6yc3eg204) - ascorbic acid 138 mg - bioferr™ 90 is indicated for the treatment of all anemias that are responsive to oral iron therapy. these include: hypochromic anemia associated with pregnancy, chronic and/or acute blood loss, metabolic disease, post-surgical convalescence, and dietary needs. hypersensitivity to any of the ingredients. hemolytic anemia, hemochromatosis, and hemosiderosis are contraindications to iron therapy.

United States - English - NLM (National Library of Medicine)

mission pharmacal company - iron (unii: e1uol152h7) (iron - unii:e1uol152h7), folic acid (unii: 935e97boy8) (folic acid - unii:935e97boy8), cyanocobalamin (unii: p6yc3eg204) (cyanocobalamin - unii:p6yc3eg204), ascorbic acid (unii: pq6ck8pd0r) (ascorbic acid - unii:pq6ck8pd0r), docusate sodium (unii: f05q2t2ja0) (docusate - unii:m7p27195ag) - ferralet ® 90 is indicated for the treatment of all anemias that are responsive to oral iron therapy. these include: hypochromic anemia associated with pregnancy, chronic and/or acute blood loss, metabolic disease, postsurgical convalescence, and dietary needs. hypersensitivity to any of the ingredients. hemolytic anemia, hemochromatosis, and hemosiderosis are contraindications to iron therapy.

United States - English - NLM (National Library of Medicine)

asclemed usa, inc. - levothyroxine (unii: q51bo43mg4) (levothyroxine - unii:q51bo43mg4), liothyronine (unii: 06lu7c9h1v) (liothyronine - unii:06lu7c9h1v) - indications and usage: np thyroid® tablets (thyroid tablets, usp) are indicated: 1. as replacement or supplemental therapy in patients with hypothyroidism of any etiology, except transient hypothyroidism during the recovery phase of subacute thyroiditis. this category includes cretinism, myxedema, and ordinary hypothyroidism in patients of any age (children, adults, the elderly), or state (including pregnancy); primary hypothyroidism resulting from functional deficiency, primary atrophy, partial or total absence of thyroid gland, or the effects of surgery, radiation, or drugs, with or without the presence of goiter; and secondary (pituitary), or tertiary (hypothalamic) hypothyroidism (see warnings). 2. as pituitary tsh suppressants, in the treatment or prevention of various types of euthyroid goiters, including thyroid nodules, subacute or chronic lymphocytic thyroiditis (hashimoto’s), multinodular goiter, and in the management of thyroid cancer. contraindications: thyroid hormone preparations are generally

United States - English - NLM (National Library of Medicine)

ascend laboratories, llc - deferasirox (unii: v8g4mof2v9) (deferasirox - unii:v8g4mof2v9) - deferasirox tablets are indicated for the treatment of chronic iron overload due to blood transfusions (transfusional hemosiderosis) in patients 2 years of age and older.  deferasirox tablets is indicated for the treatment of chronic iron overload in patients 10 years of age and older with non-transfusion-dependent thalassemia (ntdt) syndromes and with a liver iron concentration (lic) of at least 5 milligrams of iron per gram of liver dry weight (mg fe/g dw) and a serum ferritin greater than 300 mcg/l.  the safety and efficacy of deferasirox when administered with other iron chelation therapy have not been established. deferasirox is contraindicated in patients with: - estimated gfr less than 40 ml/min/1.73 m2 [see dosage and administration (2.5), warnings and precautions (5.1)]; - poor performance status [see warnings and precautions (5.1, 5.3)] ; - high-risk myelodysplastic syndromes (this patient population was not studied and is not expected to benefit from chelation therapy) ; - advanced malignancies [se

United States - English - NLM (National Library of Medicine)

trigen laboratories, llc - docusate sodium (unii: f05q2t2ja0) (docusate - unii:m7p27195ag), folic acid (unii: 935e97boy8) (folic acid - unii:935e97boy8), iron pentacarbonyl (unii: 6wq62taq6z) (ferrous cation - unii:gw89581owr), cyanocobalamin (unii: p6yc3eg204) (cyanocobalamin - unii:p6yc3eg204), ascorbic acid (unii: pq6ck8pd0r) (ascorbic acid - unii:pq6ck8pd0r) - docusate sodium 50 mg - hypersensitivity to any of the ingredients. hemolytic anemia, hemochromatosis, and hemosiderosis are contraindications to iron therapy.

United States - English - NLM (National Library of Medicine)

sterling-knight pharmaceuticals, llc - omega-3-acid ethyl esters (unii: d87ygh4z0q) (omega-3 fatty acids - unii:71m78end5s), 12-hydroxyeicosapentaenoic acid, (12r)- (unii: 78p2zc128s) (12-hydroxyeicosapentaenoic acid, (12r)- - unii:78p2zc128s), 4,7,10,13,16,19-docosahexaenoic acid, (4e,7e,10e,13e,16e,19e)- (unii: zr7nx0z98x) (4,7,10,13,16,19-docosahexaenoic acid, (4e,7e,10e,13e,16e,19e)- - unii:zr7nx0z98x) - luvira is an orally administered prescription probiotic formulation for the clinical dietary management of suboptimal nutritional status in patients where advanced supplementation is required and nutritional supplementation in physiologically stressful conditions for maintenance of good health is needed.

United States - English - NLM (National Library of Medicine)

sterling-knight pharmaceuticals, llc - omega-3 fatty acids (unii: 71m78end5s) (omega-3 fatty acids - unii:71m78end5s), 12-hydroxyeicosapentaenoic acid, (12r)- (unii: 78p2zc128s) (12-hydroxyeicosapentaenoic acid, (12r)- - unii:78p2zc128s), 4,7,10,13,16,19-docosahexaenoic acid, (4e,7e,10e,13e,16e,19e)- (unii: zr7nx0z98x) (4,7,10,13,16,19-docosahexaenoic acid, (4e,7e,10e,13e,16e,19e)- - unii:zr7nx0z98x) - luvira is an orally administered prescription omega-3-acid formulation for the clinical dietary management of suboptimal nutritional status in patients where advanced supplementation is required and nutritional supplementation in physiologically stressful conditions for maintenance of good health is needed.

United Arab Emirates - English - MOHAP (Ministry of Health & Prevention) - وزارة الصحة ووقاية المجتمع.الإمارات

new country healthcare united states of america - 90's plastic bottle - capsule - combination - nutrition , blood-oral nutrition

United Arab Emirates - English - MOHAP (Ministry of Health & Prevention) - وزارة الصحة ووقاية المجتمع.الإمارات

al hawi drug & medical equipment united states of america - 90's plastic bottle - tablet - combination - nutrition , blood-vitamins, nutrition , blood-minerals

United Arab Emirates - English - MOHAP (Ministry of Health & Prevention) - وزارة الصحة ووقاية المجتمع.الإمارات

gulf drug llc united states of america - 90's plastic bottle - tablet - combination - nutrition , blood-oral nutrition